The Impella CP device for acute mechanical circulatory support in refractory cardiac arrest

Vase, Henrik; Christensen, Steffen; Christiansen, Aage; Therkelsen, Christian Juhl; Christiansen, Evald Høj; Eiskjær, Hans; Poulsen, Søren Brandt

doi:10.1016/j.resuscitation.2016.10.003

Cited by 44 publications

(34 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All-cause in-hospital mortality was 45.1%, which is lower than previously reported. 11 Many studies evaluating outcomes of Impella use report 30-day mortality. 3,4,6,7,8,12,13 Evaluating in-hospital mortality is useful in determining immediate management of severe CS during index hospitalization.…”

Section: Discussionmentioning

confidence: 99%

“…The Impella Ventricular Support Systems received US Food and Drug Administration approval for short-term use (≤4 days for Impella 2.5 and Impella CP; ≤6 days for Impella 5.0 and Impella LD) for the treatment of CS as a result of isolated left ventricular failure. 11 No studies to date have shown improved clinical outcomes of prolonged Impella use in CS. Incidence of device complications increases with increased duration of support.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Predictors of Mortality and Outcomes of Acute Severe Cardiogenic Shock Treated with the Impella Device

Rohm

Gadidov

Leitson

et al. 2019

The American Journal of Cardiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Predictors of Mortality and Outcomes of Acute Severe Cardiogenic Shock Treated with the Impella Device

Rohm

Gadidov

Leitson

et al. 2019

The American Journal of Cardiology

View full text Add to dashboard Cite

“…Vase et al reported a survival of 50% in their case series on the use of Impella CP in refractory cardiac arrest. Majority of these patients had IHCA and VF was the initial rhythm . They concluded that it was safe and feasible to use Impella CP in these patients.…”

Section: Discussionmentioning

confidence: 96%

“…Majority of these patients had IHCA and VF was the initial rhythm. 38 They concluded that it was safe and feasible to use Impella CP in these patients. The "IMPella versus IABP Reduces mortality in STEMI patients treated with primary PCI in Severe cardiogenic SHOCK" (IMPRESS in Severe Shock) was an open-label, multi-center randomized trial which These are some potential areas where future studies may better define the role of MCS.…”

Section: Baseline Characteristicsmentioning

confidence: 99%

Temporal trends of survival and utilization of mechanical circulatory support devices in patients with in‐hospital cardiac arrest secondary to ventricular tachycardia/ventricular fibrillation

Patel

Atti

Kumar

et al. 2019

Cathet Cardio Intervent

View full text Add to dashboard Cite

Background Pulseless ventricular tachycardia/ventricular fibrillation (VT/VF) is the initial rhythm in a third of in‐hospital cardiac arrest patients. Mechanical circulatory support (MCS) device use remains poorly understood in this population. Methods We conducted an observational analysis of temporal trends in the utilization of MCS in VT/VF IHCA between January 2008 and December 2014 utilizing the Nationwide Inpatient Sample (NIS) database. Using multivariable analysis, we assessed factors associated with MCS use and survival to discharge. Results Among 151,628 hospitalizations with VT/VF IHCA, 14,981 (9.9%) received MCS. Intra‐aortic balloon pump (IABP) was the most commonly used MCS (9.1%). From 2008 to 2014, there was significant increase in the utilization of MCS (8.7–11%; ptrend < 0.0001). On multivariable analysis, there was 12‐fold increase and three‐fold increase in the utilization of PVAD and ECMO respectively; however, there was no significant change in the use of IABP. Over the seven‐year sample period, there was significant increase in the overall survival to hospital discharge (35.4–43.5%; ptrend < 0.0001). Survival to hospital discharge increased in both MCS and non‐MCS groups. Conclusion There was significant increase in utilization of MCS after VT/VF IHCA during the study period. IABP was the most commonly utilized MCS. The survival to hospital discharge increased in the overall study population including both MCS and non‐MCS groups. Future studies are needed to identify patient population most likely to benefit from the use of MCS after VT/VF IHCA.

show abstract

“…with "low-flow-time" of about 50 min is associated with a comparable survival rate to cardiogenic shock [56,57].…”

Section: Cardiac Assist Devices For Extracorporeal Life Support (Ecls)mentioning

confidence: 99%

Interventional Therapies for Post-Cardiac Arrest Patients Suffering from Coronary Artery Disease

Behnes¹,

Kuche²,

Akın³

et al. 2019

Myocardial Infarction

View full text Add to dashboard Cite

Acute myocardial infarction and coronary artery disease (CAD) are the most common causes for the development of malignant arrhythmia often leading to cardiogenic shock and cardiac arrest. Structural heart disease represents the main pathology in older patients, whereas young adults mostly suffer from cardiomyopathies and channelopathies. This book chapter delineates modern interventional therapies for patients with cardiogenic shock or aborted cardiac arrest. Epidemiological data on the incidence of malignant arrhythmia depending causing cardiac arrest depending on the presence or absence of CAD and myocardial infarction are presented. Realistic difficulties within clinical decision-making are counterbalanced for and against an early, aggressive and invasive therapeutic approach including early coronary angiography with percutaneous coronary intervention (PCI), targeted temperature management and mechanical cardiac assist devices, depending on the individual clinical presentation and underlying cardiac arrhythmia.

show abstract

The Impella CP device for acute mechanical circulatory support in refractory cardiac arrest

Cited by 44 publications

References 11 publications

Predictors of Mortality and Outcomes of Acute Severe Cardiogenic Shock Treated with the Impella Device

Predictors of Mortality and Outcomes of Acute Severe Cardiogenic Shock Treated with the Impella Device

Temporal trends of survival and utilization of mechanical circulatory support devices in patients with in‐hospital cardiac arrest secondary to ventricular tachycardia/ventricular fibrillation

Interventional Therapies for Post-Cardiac Arrest Patients Suffering from Coronary Artery Disease

Contact Info

Product

Resources

About